QualityStocksNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Releases Q2 2019 Results and Provides Operational Update

Willow Biosciences (CSE: WLLW) today released its financial results for the three and six months ended June 30, 2019 and provided an operational update. Among highlights for the quarter, the company reported that it has: expanded its operations to include three facilities located in Calgary, Alberta, Mountain View, California and Burnaby, British Columbia; made key appointments to its management team and board of directors; entered an exclusive Joint Development Agreement (“JDA”) with Noramco; and completed a reverse takeover and raised gross proceeds of approximately $37.0 million. “Over the past few months, we have made impressive progress in advancing our business on several important fronts,” Willow President and Chief Executive Officer Trevor Peters said in the news release. “We have assembled a team of proven business executives and world-renowned scientists to lead the development of our high-quality consumer, wellness, and pharmaceutical ingredient manufacturing programs. The development of our yeast-based cannabinoid production platform is progressing well and we expect to initiate the scaling up of our process in the first half of 2020. In addition to advancing our development operations, we are focused on positioning Willow for successful future commercialization through our recently signed strategic partnership with Noramco, Inc. (Noramco), one of the world’s leading pharmaceutical cannabinoid ingredient producers.”

To view the full press release, visit http://ibn.fm/TiRkj

About Willow Biosciences Inc.

Headquartered in Calgary, Canada, Willow and its team of scientists are leaders in the field of biosynthetic production of high-value, plant-derived compounds. Willow has applied its integrated suite of technologies to develop manufacturing processes for numerous active pharmaceutical ingredients with various therapeutic benefits, including cancer treatment, pain management and CNS disorders. In the cannabinoid field, Willow owns proprietary, yeast-based lab strains that produce CBD, tetrahydrocannabinol (THC) and cannabigerol (CBG), as well as certain minor and novel cannabinoids. For more information, visit the company’s website at www.WillowBio.com.

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php